Study provides proof that a child's genetic makeup can provide actionable information to alter cancer treatment regimens.
Novartis has announced that Zarxio will be available at 15% of the cost of its reference product Neupogen.
Men are opting for preventive breast surgery when diagnosed with unilateral invasive disease, a study published in JAMA Surgery has found.
Personalized telephone counseling and tailored educational materials can improve colonoscopy rates among at-risk family members of patients with colorectal cancer.
Rolapitant was approved to prevent delayed phase chemotherapy-induced nausea and vomiting in adult patients.


May 15-19, 2015
New Orleans, LA
May 29-June 2, 2015
Chicago, IL
June 11-14, 2015
Vienna, Austria
June 17-20, 2015
Lugano, Switzerland